-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145

Benzinga·10/21/2026 15:04:03
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.